CONMED prelim Q3 rev $315-318M; adj EPS growth to exceed 9-11% guide

CONMED Corp

2024-Q3 EPS reported $3.17 revenue$961,071,000

Revenue expected $315M-$318M for Q3 2024 (preliminary).
Adjusted diluted EPS growth exceeds previously guided 9%-11% range.
Full Q3 results to be reported Oct 30, 2024 after market close.
Data is preliminary; may change upon completion of financial close.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.